Abstract
SESSION TITLE: Chest Infections: Bacterial SESSION TYPE: Original Investigation Poster PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM PURPOSE: The optimal therapy for infections caused by Stenotrophomonas maltophilia (S. maltophilia) hasn't yet been established. The objective of our study is to evaluate the in vitro activity of trimethoprim/sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E, ceftazidime and to select for desired antimicrobial combinations against clinical isolated S. maltophilia. METHODS: The agar dilution method was used to test susceptibility of those candidate antimicrobials and time-killing method was carried out to evaluate the combination effect of potential drugs. RESULTS: The susceptibility to SXT, minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, chloramphenicol, polymyxin E and ceftazidime were 93.75%, 95%, 83.8%, 80%, 76.25%, 76.25%, 37.5%, 22.5% and 20% against 80 clinical consecutively isolated strains, respectively. Minocycline, tigecycline, moxifloxacin, levofloxacin, ticarcillin-clavulanate, polymyxin E, chloramphenicol and ceftazidime susceptibility were 86.4%, 72.7%, 40.9%, 40.9%, 50%, 22.7%, 13.6% and 4.5% against 22 SXT-resistant strains, respectively. In the time-killing study, synergy was found in SXT plus moxifloxacin and minocycline plus moxifloxacinat when moxifloxacin MICs≤4 µg/ml. The remaining combinations demonstrated indifferent at clinically relevant static antibiotic concentrations. No antagonisms were found in these combinations CONCLUSIONS: Minocycline and SXT may be considered as first line choices while tigecycline, moxifloxacin, levofloxacin and ticarcillin-clavulanate may serve as second line drugs in S. maltophilia infections. It may be not proper to consider ceftazidime, colistin and chloramphenicol as choices against S. maltophilia. SXT plus moxifloxacin and minocycline plus moxifloxacin may be proper combinations in serious infections CLINICAL IMPLICATIONS: Our studies provide some references for doctors to choose proper drugs and combinations in clinical settings. DISCLOSURE: The following authors have nothing to disclose: Chuanqi Wei No Product/Research Disclosure Information
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
